Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.62
+0.29 (3.48%)
At close: Oct 13, 2025, 4:00 PM EDT
8.62
0.00 (0.00%)
After-hours: Oct 13, 2025, 6:33 PM EDT
Novavax Revenue
Novavax had revenue of $239.24M in the quarter ending June 30, 2025, a decrease of -42.42%. This brings the company's revenue in the last twelve months to $1.08B, up 9.22% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.08B
Revenue Growth
+9.22%
P/S Ratio
1.24
Revenue / Employee
$1,133,107
Employees
952
Market Cap
1.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NVAX News
- 6 days ago - Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - PRNewsWire
- 13 days ago - Novavax Announces Progress on Sanofi Agreement - PRNewsWire
- 5 weeks ago - Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment - PRNewsWire
- 5 weeks ago - Novavax to Participate in the Cantor Global Healthcare Conference - PRNewsWire
- 6 weeks ago - Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. - PRNewsWire
- 7 weeks ago - Novavax Announces Convertible Debt Refinancing - PRNewsWire
- 2 months ago - Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha